The approval was based on data from the randomized, double-blind, placebo-controlled phase 3 SELECT-GCA trial.

Intracranial GCA appears to be more common than previously thought and is linked to higher rates of stroke and mortality.

The FDA has approved the Janus kinase inhibitor upadacitinib for the treatment of giant cell arteritis in adults, the first such approval in the disease since tocilizumab received the green light in ...

Individuals with type 2 diabetes or a higher BMI may face a reduced risk of developing GCA, while a history of cardiovascular disease may increase this risk.

Findings showed 46.4% of patients treated with upadacitinib 15mg achieved sustained remission compared with 29.0% of those who received placebo. The Food and Drug Administration (FDA) has approved ...

Patients with giant cell arteritis have a greater risk for aortic complications than those with polymyalgia rheumatica.

for the treatment of adults with giant cell arteritis (GCA). 1 This comes after the European Commission recently granted marketing authorization of RINVOQ for the treatment of GCA in adult patients.

AbbVie recently secured FDA approval for RINVOQ to treat giant cell arteritis, which alongside a biologics license application for TrenibotE, underscored the company's focus on innovation.

The US Food and Drug Administration (FDA) has approved a new indication for upadacitinib as a treatment for giant cell arteritis (GCA) in adults. This is the first oral JAK inhibitor indicated for ...

Giant cell arteritis is a systemic vasculitis and careful ... In a 2001 meta-analysis that included 941 biopsy proven cases of GCA, 4% of those with positive biopsies had "normal" ESRs.